semaglutide alzheimer's clinical trial in early-stage Disease Associations of semaglutide with first‐time

For metabolic endpoints, the relatively concentrated distributions imply that efficacy is highly predictable, supporting certainty-based selection in clinical practice

In another study, a case report of a 54-year-old Caucasian female with type 2 diabetes treated with a 3 drugs regimen, 1 of which was a GLP-1 agonist (Liraglutide) after which she experienced confusion and an episode of hypoglycemia for which she was hospitalized and found to have a pancreatic mass that was confirmed to be a benign insulinoma

GLP-1s are becoming increasingly popular as first-choice medications for obesityrelative to other drugs such as metformin and Qsymiabecause of changing patient preferences, differences in effectiveness, and the positive effects of GLP-1s on comorbidities, such as type 2 diabetes mellitus and hypertension

Kaneto, S

Regular check-ins during the first 48 weeks allow for real-time adjustments that prevent dizziness from escalating into treatment discontinuation